Company Release no. 21/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 12 December 2019   Veloxis Pharmaceuticals: Publication of Offer Document and Board Statement   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO

Selskabsmeddelelse nr. 21/2019 Til: NASDAQ Copenhagen A/S København, Danmark 12. december 2019   Veloxis Pharmaceuticals: Offentliggørelse af Tilbudsdokument og Bestyrelsens Redegørelse   MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION,

Company Release no. 20/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 5 December 2019   Veloxis In creases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 19/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 2 December 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 18/2019 To: NASDAQ Copenhagen A/S  Copenhagen, Denmark, 25 November 2019 Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD

Selskabsmeddelelse nr. 18/2019 Til: NASDAQ Copenhagen A/S København, Danmark, 25. november 2019   Asahi Kasei Group offentliggør anbefalet betinget, frivilligt offentligt købstilbud på Veloxis MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN

Company Release no. 17/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 12 November 2019   Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2019   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim

Company Release no. 16/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 31 October 2019   Veloxis Increases Outlook for 2019 Based on Continued Strong Performance   Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its

Company Release no. 15/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 05 September 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 14/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 23 August 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased

Company Release no. 13/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 13 August 2019 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and

Company Release no. 12/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 08 August 2019 Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2019 Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report

Company Release no. 11/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 22 July 2019 Veloxis Revises Outlook for 2019 Based on Strong Performance Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its Outlook for 2019.  This

Company Release no. 10/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 03 June 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 09/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 07 May 2019   Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program     Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue

Company Release no. 08/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 06 May 2019   Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2019   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim

Company Release no. 07/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 04 April 2019 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and

Company Release no. 06/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 03 April 2019   Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019   Summary: At Veloxis Pharmaceuticals A/S’ Annual General Meeting held earlier today,

Company Release no. 05/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 02 April 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 04/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 20 March 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 03/2019 To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 12 March 2019 Notice to Convene Annual General Meeting 2019 The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the annual